Globus Medical, Inc. (NYSE:GMED) dropped -1.37% and closed the trade at $ 22.34. The company recorded a trading capacity of 1.39 million shares above its three months average daily volume of 720.78 thousand shares. During the last trade, shares reached to high price of $22.68 and touched the low price of $22.17. The stock’s 50-day moving average is noted at $23.21 and its 200-day moving average is stands at $23.96.
Additionally, the company has a PE ratio of 18.31 and has EPS of 1.22. The company has market capitalization of $2.14B.
Currently Globus Medical, Inc. (GMED) captured an average recommendation of “ Overweight ” from analysts, according to FactSet data. The stock has been suggested as “Buy” from “7″ Analysts”. “0” rated “Sell” for the company. “5” said the company as a “Hold”. Overweight rating was given by “0” and Underweight rating was given by “1”.
Analysts are expecting that the company to achieve $27.10 Price Target in next 52-weeks, average price is come up through the consensus of analysts. High potential price target is set at $33.00 however minimum price target advised by analysts is $23.00. The Median price target for the stock is measured at $27.00.
Presently, Analysts decided consensus EPS estimate of $0.28 for present quarter and one month ago projected EPS estimate was at $0.29. If we take a look at back 3 month ago, consensus EPS estimate was $0.30.
A current consensus EPS estimate for next quarter is at $0.33 and 3 month ago EPS forecast was $0.32. Have a look at back 1 month ago, consensus EPS forecast was seen at $0.33.
For current fiscal year, most recent EPS estimate is set at $1.20 based on Analyst consensus and three month ago consensus EPS opinions was at $1.20. During period one month ago, consensus EPS forecast was decided at $1.20.
A current consensus EPS projection for next fiscal year is observed at $1.30 and one month ago consensus EPS forecast was at $1.30. Take a look at back three month ago, consensus EPS estimate opinions was decided at $1.31 by analysts.
One Month ago, the stock has gained consensus mean rating of Overweight based on the analysis of brokerage analyst firms polled. 7 presented the recommendations about the stock as a “Buy” signal and “Overweight” signal was reported by 0. 5 advised the “Hold” rating about this stock. 0 revealed “Sell” signal and “Underweight” rating was declared by 1.
Three Months Ago, Analysts recommended an average brokerage rating of Overweight derived from brokerage firms, according to FactSet. 11 said a “Buy Rating” and 0 announced “Overweight Rating”. 1 advised “Hold Rating” regarding the stock. 1 announced “Sell Rating” and 1 disclosed “Underweight Rating”.